Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2025-12-25 @ 5:32 PM
Study NCT ID:
NCT05765604
Status:
COMPLETED
Last Update Posted:
2025-03-26
First Post:
2023-03-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
Sponsor:
WestVac Biopharma Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-14
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-03-30
Completion Date Type:
ACTUAL
First Submit Date:
2023-03-10
First Submit QC Date:
None
Study First Post Date:
2023-03-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-24
Last Update Post Date:
2025-03-26
Last Update Post Date Type:
ACTUAL